NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submissio ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of ELEVIDYS, concealing significant risks to patients [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to the halting of recruitment and dosing in trials, attracting regulatory scrutiny [2]. - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified period (June 22, 2023, to June 24, 2025) have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=158125&from=4CLASS PERIOD: June 22, 2023 to J ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - Defendants are accused of making false statements about the safety risks associated with ELEVIDYS [2]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff must file papers by August 25, 2025, but participation as a class member does not require serving as lead plaintiff [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4].

Group 1 - Sarepta Therapeutics (SRPT) has experienced a significant decline in stock value, down more than 90% year-to-date [1] - The company has faced a series of negative events, including paused drug shipments and patient deaths [1]

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Impact - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. - Following the announcement of patient deaths related to Elevidys, Sarepta's stock experienced significant declines, with a drop of over 27% on March 18, 2025, and a further decline of more than 42% on June 16, 2025 [4][5]. Legal Proceedings - The case is pending in the U.S. District Court for the Southern District of New York, with investors having until August 25, 2025, to seek lead plaintiff status [2].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The complaint alleges that Sarepta made false statements regarding its gene therapy ELEVIDYS, claiming it posed significant safety risks to patients [2] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential halting of recruitment and dosing in trials, attracting regulatory scrutiny [2] - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's safety and approval status [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4]

Core Opinion - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization for Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD) in ambulatory children aged three to seven years [1][2]. Group 1: Clinical Data and Efficacy - The CHMP's opinion was based on data from the largest gene therapy clinical program for DMD, including the pivotal Phase 3 EMBARK study, which indicated that Elevidys provided sustained stabilization or slowing of disease progression [2]. - Over 900 individuals with DMD have been treated with Elevidys, with 760 being ambulatory; although the primary endpoint was not met in EMBARK after one year, significant improvements were observed in secondary endpoints compared to placebo [3]. - Longer-term efficacy data submitted to the EMA included two-year results from the EMBARK study and a three-year pooled efficacy analysis from other studies, showing clinically meaningful improvements in motor function [4]. Group 2: Regulatory and Market Impact - Sarepta Therapeutics announced a voluntary and temporary pause of all U.S. shipments of Elevidys effective July 22, following a senior FDA official's statement that additional clinical data would be required to validate Elevidys' safety profile [4][5]. - Analysts expressed uncertainty regarding the FDA's requirements for resuming shipments, noting that requiring another trial for ambulatory patients would be unusual given Elevidys' existing full approval for that group [6]. - The stock price of Sarepta Therapeutics fell by 7.53% to $11.91, reflecting market pressure due to the ongoing uncertainty surrounding the product's status [9]. Group 3: Partnerships and Financial Implications - Arrowhead Pharmaceuticals reported that Sarepta has faced setbacks in unrelated products and programs, but expects to earn the first $100 million soon and the remaining $200 million by year-end [8]. - Should Sarepta fail to meet payment milestones associated with the enrollment of ARO-DM1 cohorts, Arrowhead would have the right to terminate the agreement regarding ARO-DM1 [9].